Additional file 1 of Development of human targeted extracellular vesicles loaded with shRNA minicircles to prevent parkinsonian pathology

Additional file 1. Supplementary Methods. Fig. S1. Human dendritic cells characterization. Fig. S2. In vivo organ biodistribution of human RVG-EVs. Fig. S3. Alpha-synuclein downregulation in contralateral brain regions of mice treated with anti-alpha-synuclein shRNA-MC delivered by h-RVG-EV. Fig. S4. Quantification of TH protein levels in midbrain. Fig. S5. Immunofluorescence images of total alpha-synuclein in cord and intestinal sections and immunohistochemical images of phosphorylated alpha-synuclein in intestine. Table S1. Changes in gene expression. Table S2. Inflammatory cytokine levels in PFFs alpha-synuclein treated mice analyzed 90 days after the first treatment. Uncropped Western blots.